

ANTI-CYTOTOXIC AND ANTI-INFLAMMATORY EFFECTS OF THE MACROLIDE ANTIBIOTIC ROXITHROMYCIN IN SULFUR MUSTARD-EXPOSED HUMAN AIRWAY EPITHELIAL CELLS

Xiugong Gao^{1*}, Radharaman Ray², Yan Xiao³, Peter E. Barker³ and Prabhati Ray¹

¹Walter Reed Army Institute of Research
Silver Spring, MD 20910

²United States Army Medical Research Institute of Chemical Defense
Aberdeen Proving Ground, MD 21010

³National Institute of Standards and Technology
Gaithersburg, MD 20890

ABSTRACT

Inhalation of sulfur mustard (SM) causes airway inflammation and injury. There is increasing evidence of the effectiveness of macrolide antibiotics in treating chronic airway inflammatory diseases. In this study, the anti-cytotoxic and anti-inflammatory effects of a representative macrolide antibiotic, roxithromycin, were tested *in vitro* using SM-exposed normal human small airway epithelial (SAE) cells and bronchial/tracheal epithelial (BTE) cells.

Cells were exposed to varying concentrations of SM with or without roxithromycin. Cytotoxicity was measured with the MTS assay and Calcein AM/ethidium homodimer (EthD-1) fluorescence staining. Cytokine protein expression was analyzed by enzyme-linked immunosorbent assay (ELISA) and cytokine mRNA expression by real-time RT-PCR. Inducible nitric oxide synthase (iNOS) protein expression was examined by a new immunocytochemical method using quantum dots as the fluorophore.

Our results show that roxithromycin decreased SM cytotoxicity in both SAE and BTE cells. Also, roxithromycin inhibited the SM-stimulated overproduction of the proinflammatory cytokines interleukin (IL)-1 β , IL-6, IL-8 and TNF at both the mRNA level and the protein level. In addition, roxithromycin inhibited the SM-induced overexpression of iNOS.

In conclusion, the present study demonstrates that roxithromycin has anti-cytotoxic and anti-inflammatory activities in human airway epithelial cells that likely depend on the ability of roxithromycin to down-regulate the production of proinflammatory mediators and cytokines, and suggests that macrolide antibiotics may serve as potential vesicant respiratory therapeutics through mechanisms independent of their antibacterial activity.

1. INTRODUCTION

2,2'-Dichlorodiethyl sulfide (sulfur mustard, SM) is a vesicant agent that was used as a chemical weapon during World War I and more recently during the Iran-Iraq conflict; therefore, it remains a significant military and civilian threat (Smith and Dunn, 1991). Damage due to SM inhalation has been found to be dose-dependent (Eisenmenger et al., 1991; Papirmeister et al., 1991). At low to moderate doses, the upper respiratory tract is mostly affected, whereas at higher doses, damage is seen in the lower lung, including the alveoli. SM-induced epithelial cell injury and cell death in the tracheobronchial tree leads to inflammation and sloughing of the mucosa during acute stages. The clinical signs of SM inhalation include asthma, chronic bronchitis, bronchiectasis, and pulmonary fibrosis (Emad and Rezaian, 1997). Pulmonary damage and associated secondary infections have been responsible for most fatalities (Papirmeister et al., 1991). At present, there is no effective therapy for the victims due to lack of understanding of the pathophysiological processes of SM inhalation injury.

SM acts as an electrophile that alkylates cellular and extracellular components of living tissue. As a result, complex cellular events develop, including cell cycle arrest, the synthesis and release of inflammatory mediators, and cytotoxicity. Following these cellular effects are tissue responses such as inflammation and tissue damage (Amir et al., 2000). The cause of the acute injury appears to be the premature, sudden and massive release of destructive enzymes and mediators of inflammation such as proinflammatory cytokines, including interleukin (IL)-1 β , IL-6, IL-8 and tumor necrosis factor (TNF), and inducible nitric oxide synthase (iNOS).

Proinflammatory cytokines are essential mediators of cell-to-cell signals in physiological and pathological immune responses and in the inflammatory response.

Report Documentation Page				Form Approved OMB No. 0704-0188	
Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.					
1. REPORT DATE 01 NOV 2006		2. REPORT TYPE N/A		3. DATES COVERED -	
4. TITLE AND SUBTITLE Anti-Cytotoxic And Anti-Inflammatory Effects Of The Macrolide Antibiotic Roxithromycin In Sulfur Mustard-Exposed Human Airway Epithelial Cells				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S)				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Walter Reed Army Institute of Research Silver Spring, MD 20910				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release, distribution unlimited					
13. SUPPLEMENTARY NOTES See also ADM002075., The original document contains color images.					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT UU	18. NUMBER OF PAGES 32	19a. NAME OF RESPONSIBLE PERSON
a. REPORT unclassified	b. ABSTRACT unclassified	c. THIS PAGE unclassified			

Under normal conditions, these cytokines act as crucial signals in the development of appropriate defenses. However, exaggerated or prolonged release can lead to pathological conditions (Sabourin et al., 2000).

iNOS is the inducible isoform of nitric oxide synthase, the enzyme that catalyzes the synthesis of nitric oxide (NO), a short-lived free radical gas and a pleiotropic mediator involved in the regulation of vascular smooth muscle tone and proliferation, cell-mediated immunity, and inflammation (Sase and Michel, 1997; Nussler and Billiar, 1993). However, NO can exert deleterious effects when it is inappropriately generated or overproduced, and excessive amounts of NO and its metabolites, such as peroxynitrite, may contribute to the pathophysiology of inflammation and the resultant tissue damage (Gaston et al., 1994; Stamler et al., 1992; Kooy et al., 1995). Production of NO is upregulated in a variety of inflammatory diseases in which iNOS may be involved (Maziak et al., 1998; Kharitonov et al., 1995).

Macrolides are a group of antibiotics that were initially discovered because of their antibacterial properties. The name “macrolide” is derived from their structure, which is characterized by a macrocyclic lactone ring with various amino sugars attached (Bryskier et al., 1993). Roxithromycin is one of the commonly used macrolides approved by the FDA (Young et al., 1989). In recent years, there has been increasing evidence of the effectiveness of macrolide antibiotics in treating chronic airway inflammatory diseases through mechanisms distinct from their antibacterial activity (for review see Rubin, 2004). Although the mechanisms underlying this effect are still unclear, macrolides have been shown to affect several pathways of the inflammatory process, including the migration of neutrophils, the oxidative burst in phagocytes, and the production of proinflammatory cytokines (Konno et al., 1994). In this study, the anti-cytotoxic and anti-inflammatory effects of roxithromycin were tested using normal human small airway epithelial (SAE) cells and bronchial/ tracheal epithelial (BTE) cells exposed to SM as *in vitro* models. Cell viability and expression of proinflammatory cytokines and iNOS were examined.

2. MATERIALS AND METHODS

2.1 Reagents

Sulfur mustard (2,2'-dichlorodiethyl sulfide; 4 mM) was acquired from the US Army Edgewood Research, Development and Engineering Center (Aberdeen Proving Ground, MD). Roxithromycin was obtained from Sigma (St. Louis, MO) and dissolved in ethanol at a concentration of 10 mM and then diluted to the desired concentrations using culture medium.

2.2 Cell Culture

Normal human SAE cells and normal human BTE cells were obtained from Cambrex (Walkersville, MD). Cells were grown in the optimized media as formulated by the manufacturer and cultured at 37°C under humidified 5% CO₂. Experiments were performed on cells of the fourth passage.

2.3 Sulfur Mustard Exposure

Cells were seeded in 6-, 12-, 24- or 96-well plates and allowed to grow for 5 to 6 days to near confluence. The medium was replaced with fresh medium before exposure. SM was then added to the final concentrations indicated. The culture plates were maintained at room temperature in a chemical fume hood for 1 hr then transferred to an incubator of 37°C with 5% CO₂. In cases where roxithromycin was used, it was added to the culture immediately before the SM exposure.

2.4 Cytotoxicity Assay

Cytotoxicity was measured by either the MTS assay or Calcein AM/ethidium homodimer-1 (EthD-1) staining. The CellTiter 96[®] Aqueous One Solution Cell Proliferation Assay kit from Promega (Madison, WI) was used for the MTS assay and instructions from the manufacturer were followed. Briefly, cells were seeded in a 96-well plate at 1×10^4 cells/well and allowed to adhere overnight at 37°C with 5% CO₂, then cells were exposed to SM with or without roxithromycin and incubated for another 24 hr. After adding 20 µl of assay reagent to each well that contained 100 µl medium, cells were further cultured for 3 hr and the resultant absorbance was recorded at 490 nm using a 96-well plate reader. Each experiment was performed with eight independent replicates and repeated three times. For the Calcein AM/EthD-1 staining method, the LIVE/DEAD[®] Viability/Cytotoxicity Kit from Molecular Probes (Eugene, OR) was used and protocols provided by the manufacturer were adopted.

2.5 Enzyme-Linked Immunosorbent Assay (ELISA)

ELISA kits from BD Biosciences (San Diego, CA) were used for the quantification of IL-1β, IL-6, IL-8, and TNF in the culture medium following the manufacturer's instructions. The results are expressed as a percentage of the control (cells unexposed to SM) and represent the mean ± SE of three experiments performed in triplicate.

2.6 Real-Time RT-PCR

Total RNA was isolated from $\sim 1 \times 10^7$ cells of each sample, using the RNeasy[®]-4PCR kit from Ambion (Austin, TX) following the manufacturer's instructions

and with the optional DNase I treatment step to avoid contamination with genomic DNA. Reverse transcription of mRNA was carried out using the High-Capacity cDNA Archive Kit from Applied Biosystems (Foster City, CA), using 1 µg of total RNA in an 100-µl final volume. Real-time PCR was carried out on the 7500 Fast Real-Time PCR system of Applied Biosystems using TaqMan Gene Expression Assays primer/probe sets and the standard thermal-cycling conditions for relative quantification designed by the manufacturer. Results were analyzed with the SDS software v1.3.0 on the system using the $2^{-\Delta\Delta C_T}$ method. β -actin was used as an endogenous control to correct for variations in input RNA amount and cDNA amplification of different samples.

2.7 Immunofluorescence Staining

Cells were grown on slide to 30-40% confluence and exposed to SM with or without roxithromycin. After 24 hr, cells were rinsed with 10 mM Tris, 150 mM NaCl, pH 7.4 (TBS) and fixed in 10% zinc formalin solution. The slides were then processed robotically on the BenchMark XT IHC/ISH workstation of Ventana (Tucson, AZ) to react with the primary and secondary antibodies. The primary antibody used was mouse anti-iNOS MAb from BD Biosciences, and was diluted 1:1000 in TBS + 0.5% (w/v) Triton X-100 (TBST). The secondary antibody was pre-diluted biotinylated rabbit anti-mouse IgG from Ventana. iNOS signals were detected by quantum dot-streptavidin conjugates (streptavidin-Qdot655), which was diluted 1:200 with the Qdots incubation buffer from Invitrogen (Carlsbad, CA). The fluorescence signals were visualized, captured and processed as reported previously (Xiao and Barker, 2004; Xiao et al., 2005).

2.8 Data Analysis

For comparative studies, Student's *t*-test (unpaired) or one-way ANOVA tests (with Bonferroni post test if $P < 0.05$) were used for statistical analysis. Differences were considered statistically significant if a *P* value of < 0.05 was achieved.

3. RESULTS

3.1 Cytotoxicity

The MTS assay showed that SM exerted cytotoxicity in a concentration-dependent manner in SAE and BTE cells. At 10 µM, no significant decrease in cell viability was observed. At 100 µM, however, SM caused severe toxicity: the viability of both cell types decreased to ~20% compared with untreated cells 24 hr after exposure (Fig. 1). In contrast, roxithromycin reduced SM cytotoxicity in SAE and BTE cells; incubation with 100 µM roxithromycin increased the cell viability from

~20% to ~50% and ~60% for SAE and BTE cells, respectively, 24 hr after exposure to 100 µM SM (Fig. 2). No significant protective effects of roxithromycin were observed at concentrations lower than 10 µM. Roxithromycin alone had no effects on cell viability of SAE and BTE cells at the concentration range tested (0.1~100 µM, data not shown).




Figure 1. Cytotoxicity of SM on SAE and BTE cells. Cells were exposed to various concentrations of SM. Cell viability was measured using the MTS assay 24 hr after exposure, and is expressed as a percentage of the control (unexposed cells, “C”). **** $P < 0.001$ versus control.




Figure 2. Effect of roxithromycin on SM cytotoxicity in SAE and BTE cells. Various concentrations of roxithromycin were added to the cell suspension immediately before exposure to 100 µM SM. Cell viability was measured using the MTS assay 24 hr after exposure, and is expressed as a percentage of the value obtained from cells unexposed to SM (“U”). **** $P < 0.001$ versus control (cells exposed to SM without roxithromycin, “C”).

Calcein AM/EthD-1 staining showed a similar protective effect of roxithromycin on SM-exposed SAE and BTE cells (Fig. 3). Exposure to 100 µM SM caused significant cell death compared to control (unexposed) cells, whereas the number of live cells increased substantially when 100 µM roxithromycin was included. Roxithromycin (100 µM) alone had no effect on cell viability.

Previous studies have implied that inflammatory cytokines or mediators are involved in SM-induced

injuries and cell death; for example, suppressed expression of the proinflammatory cytokines IL-8 and IL-6 in human epidermal keratinocytes led to increased viability of SM-treated cells (Qabar et al., 2005). In order to understand the mechanism of the protective effect of roxithromycin and verify if the decreased cytotoxicity is due, at least in part, to a reduced inflammation, we further evaluated the effect of roxithromycin on the expression of some inflammatory mediators, including proinflammatory cytokines and iNOS, at the mRNA and/or protein level.




Figure 3. Anti-cytotoxicity effect of roxithromycin on SM-treated SAE (A) and BTE (B) cells. Roxithromycin was added to the cell suspension immediately before SM exposure. Cell viability was examined by Calcein AM/EthD-1 fluorescence staining 24 hr after exposure. *a*) control (unexposed), *b*) 100 μ M roxithromycin, *c*) 100 μ M SM, and *d*) 100 μ M SM + 100 μ M roxithromycin. Cells stained green were alive and those stained red dead.

3.2 Cytokine Protein Expression

SM stimulated release of proinflammatory cytokines (IL-1 β , IL-6, IL-8 and TNF) from SAE and BTE cells into the culture medium, albeit the extent of stimulation varied among different cytokines. A time-course study of cytokine release from cells exposed to ≤ 100 μ M SM indicated that, for both cell types, accumulation of all the cytokines reached maximum levels 24 hr after exposure and remained stable for at least 48 hr (data not shown). Therefore, in the following experiments all the cytokines were measured 24 hr post-exposure. In general, it was found that SM exposure induced proinflammatory cytokine release in a concentration-dependent manner, and roxithromycin inhibited the cytokine release, also in a concentration-dependent manner. We noticed that the absolute concentrations of cytokines measured in the culture supernatant were not consistent among replicated experiments, probably due to differences in cell number, confluence, age and other unknown factors; however, when the concentration values were normalized relative to control (unexposed) cells, the data became fairly consistent. For this reason, the results are presented as percentages of the control in each experiment.

IL-8. Culture medium harvested from control SAE cell cultures showed a gradual accumulation of this cytokine over time that reached a plateau by 24 hr. Upon

treatment with <10 μ M SM, no significant difference compared to the control situation was observed. When treated with 100 μ M SM, however, a significantly higher amount of IL-8 was released from SAE cells after 5 hr and the accumulation of the cytokine persisted up to 24 hr after exposure (data not shown). The final concentration, in the range of 20–30 ng/ml among experiments, was about 12-fold higher than control cells. When roxithromycin was added to the SAE cell culture medium immediately before SM exposure, concentration-dependent inhibition of the SM-induced cytokine secretion was observed (Fig. 4). Inhibition was observed at a concentration as low as 1 μ M and reached 71% when the concentration of roxithromycin was 100 μ M. Very similar results were observed for BTE cells, except that the highest concentration of IL-8 released into the medium was in the range of 12–18 ng/ml when cells were exposed to 100 μ M SM.




Figure 4. Inhibition by roxithromycin of cytokine release from SM-exposed SAE cells. Various concentrations of roxithromycin were added to the cell suspensions immediately before exposure to SM. Cytokine release was measured by ELISA 24 hr after exposure. Cytokine concentration is expressed as a percentage of the control (unexposed) cells. RXM, roxithromycin. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$ versus cells exposed to SM only.

IL-6. Similar to IL-8, culture medium harvested from control SAE cell cultures showed a gradual accumulation of IL-6 over time that reached a plateau by 24 hr. Upon treatment with <10 μ M SM, no significant difference compared to the control situation was observed. When treated with 100 μ M SM, however, a significantly higher amount of IL-6 was released from SAE cells after 3 hr and accumulation of the cytokine persisted up to 24 hr after exposure (data not shown). The final concentration, in the range of 3–5 ng/ml among experiments, was 8-fold as high as the control cells. When roxithromycin was added to the SAE cell culture medium immediately before SM exposure, concentration-dependent inhibition of SM-induced cytokine secretion was again observed (Fig. 4). The inhibition was observed at a concentration as low as 1 μ M and reached 70% when the concentration of roxithromycin was 100 μ M. Very similar results were observed for BTE cells, except that the range of the

highest concentration of IL-6 released into the medium was 4–6 ng/ml for cells exposed to 100 μ M SM.

IL-1 β . Unlike IL-6 and IL-8, IL-1 β concentration in the culture medium of SAE cells remained low even when the cells were treated with 100 μ M SM (<100 pg/ml). Nevertheless, statistically significant concentration-dependent stimulation by SM and concentration-dependent inhibition by roxithromycin were observed. IL-1 β concentration in the culture medium increased to 6-fold compared with control cells 24 hr after exposure to 100 μ M SM (Fig. 4). Inhibition by 100 μ M roxithromycin was 69%. Very similar results were observed for BTE cells, except that the highest concentration of IL-1 β released into the medium was ~80 pg/ml upon 100 μ M SM exposure.

TNF. Similar to IL-1 β , the concentration of TNF in the culture medium of SAE cells also remained low (<50 pg/ml) even when treated with 100 μ M SM. Nevertheless, concentration-dependent stimulation by SM and concentration-dependent inhibition by roxithromycin were observed. TNF concentration in the culture medium increased ~4-fold compared with control cells 24 hr after exposure to 100 μ M SM and inhibition by 100 μ M roxithromycin was 73% (Fig. 4). Very similar results were observed for BTE cells.

3.3 Cytokine mRNA Expression

The mRNA expression levels of the proinflammatory cytokines in SAE cells were in good agreement with their protein expression patterns obtained from the ELISA experiments. At the mRNA level, SM exposure also induced proinflammatory cytokine expression in a concentration-dependent manner (data not shown). Exposure to 100 μ M SM increased cytokine mRNA expression substantially (Fig. 5); for IL-6, IL-8 and TNF, the fold increase was even higher than that of the protein release level measured by ELISA (18-, 12-, and 8-fold vs. 12-, 8-, and 4-fold, respectively). For IL-1 β , the increase in its mRNA level was slightly lower than its increase in protein secretion (4-fold vs. 6-fold). Treatment with roxithromycin of the SM-exposed cells decreased the mRNA levels. This inhibitory effect of roxithromycin on mRNA expression was also concentration dependent (Fig. 5). 100 μ M roxithromycin was effective in reducing the mRNA expression close to normal levels. Similar results were obtained for BTE cells.

3.4 iNOS Expression

iNOS is difficult to detect in airway epithelial cells by western blotting or conventional immunocytochemical methods, primarily due to its very low basal level expression. Results from real-time RT-PCR experiments indicated that the iNOS mRNA level was 10^3 – 10^5 times

lower than that of some of the proinflammatory cytokines (data not shown). In this study, we used quantum dots, a new nano-scale material, as the fluorophore in the immunocytochemical detection of iNOS. Because of the high stability, intensity, and signal-to-noise ratio of the fluorescence signal of quantum dots, iNOS was easily detectable in both control (unexposed) and SM-exposed SAE and BTE cells.




Figure 5. Inhibition by roxithromycin of cytokine mRNA expression in SM-exposed SAE cells. Various concentrations of roxithromycin were added to the cell suspensions immediately before exposure to SM. Total RNA was isolated from cells 24 hr after exposure. Cytokine mRNA was quantified using real-time RT-PCR. Results are expressed as a percentage of the control (unexposed) cells. RXM, roxithromycin. * P < 0.05, ** P < 0.01, *** P < 0.001 versus cells exposed to SM only.

Using this new immunocytochemical method we have found that, in both SAE and BTE cells, SM caused overexpression of iNOS, and this effect was inhibited by roxithromycin. Shown in Fig. 6 are immuno-fluorescence staining images using streptavidin-conjugated quantum dots as detectors. Results from the statistical analysis of the fluorescence signals are shown in Fig. 7. Exposure to 100 μ M SM dramatically increased iNOS expression in the two cell types (>10-fold). However, when 100 μ M roxithromycin was added to the culture medium immediately before SM exposure, iNOS expression was reduced substantially, to a level comparable to the basal level. Roxithromycin (100 μ M) alone had no effect on the signal level detected (data not shown).

4. DISCUSSION

SM inhalation causes acute airway inflammation and tissue injury, presumably due to the premature, sudden and massive release of destructive enzymes and mediators of inflammation (Papirmeister et al., 1991). Currently there are no effective antidotes for SM-induced inflammation and injury. Macrolide antibiotics have been reported to have immunomodulatory effects and to be effective in treatment of chronic airway inflammation

through actions other than their bactericidal activity (Rubin, 2004). In this study, we evaluated the potential of macrolide antibiotics as antidotes for SM-induced injury and inflammation using roxithromycin as a representative macrolide antibiotic for the tests.




Figure 6. Effect of roxithromycin on iNOS expression in SM-exposed SAE (A) and BTE (B) cells. *a*) control; *b*) 100 μ M SM; *c*) 100 μ M SM + 100 μ M roxithromycin. Representative 2D images from each sample are shown. The scale bar in each image represents 20 μ m.




Figure 7. Relative fluorescence intensity showing quantitatively the effect of roxithromycin on iNOS expression in SM-exposed SAE and BTE cells. Average fluorescence intensities were computed from cells ($n \geq 10$) in each sample and are expressed relative to the control (unexposed cells). RXM, roxithromycin. *** $P < 0.001$ versus cells exposed to SM only.

Airway inflammation and injury by SM is a complex phenomenon that involves airway epithelial cells, cilia cells, goblet cells and smooth muscle cells interacting with one another under the control of a network of cytokines and other mediators. SAE and BTE cells are considered the first line of defense against inhaled chemicals as they are in direct contact with these chemicals and participate in the pathogenesis of airway injury through the release of oxidants and inflammatory cytokines. It is therefore important to understand the interaction between these cells and the chemical insult, as well as their response to an insult/therapeutic treatment combination such as SM/roxithromycin.

The effect of roxithromycin on SM-induced cell injury was first tested by the MTS cell viability assay and

the Calcein AM/EthD-1 fluorescence staining viability assay. The MTS assay showed a concentration-dependent cytotoxicity induced by SM in SAE and BTE cells. For both cell types, 100 μ M roxithromycin alleviated the SM cytotoxicity. Calcein AM/EthD-1 fluorescence staining confirmed these results. Together, these results demonstrated the protective effect of roxithromycin against SM-induced injury.

Proinflammatory cytokines play a major role in both acute and chronic inflammatory processes, including those produced by SM. However, these cytokines, particularly when produced in excess, can be pathogenic. Previous studies demonstrated that *in vivo* damage to the skin by SM results in an immunological response defined by increased gene expression of the inflammatory cytokines (Sabourin et al., 2000). In this study we examined the expression of four major inflammatory cytokines, IL-1 β , IL-6, IL-8, and TNF. The basal expression levels of the four cytokines were all very low in normal SAE and BTE cells, although IL-6 and IL-8 accumulated continuously in the culture medium from unstimulated cells grown in cell culture. However, exposure of SAE and BTE cells to SM *in vitro* resulted in a rapid increase in the mRNA levels in the cell and the release of the cytokine protein into culture supernatants for all of the four cytokines. Both the mRNA expression and protein release increased several fold in SM-exposed cells relative to unexposed cells for IL-1 β and TNF, and increased 10- to 20-fold in the cases of IL-6 and IL-8. Although the final supernatant concentrations for IL-1 β and TNF remained low (<100 pg/ml), the concentrations of IL-6 and IL-8, on the other hand, reached very high levels (10-30 ng/ml). These results suggest that these two inflammatory mediators may play a major role in the mediation of the inflammatory and immune responses initiated by SM inhalation.

In light of the potential role of IL-6 and IL-8 in inflamed airway epithelium, an understanding of the regulation of their production may provide valuable information for treatment of SM exposure. A significant increase in IL-8 release was also reported in human epidermal keratinocytes following SM exposure and has been proposed as a biomarker for SM-induced inflammation (Arroyo et al., 1999). It is also intriguing to note that IL-6 was reported as an anti-inflammatory cytokine in human plasma samples (Tilg et al., 1994) and in human monocytes (Morikawa et al., 1993). Therefore, it is reasonable to speculate that IL-6 is a pleiotropic cytokine whose anti- or pro-inflammatory properties depend on the cell type from which it is produced and to which it is targeted.

iNOS has been suggested to be an important biomarker of inflammation, as its overexpression leads to excessive production of NO, which contributes to the

pathophysiology of inflammation and the resultant tissue damage (Gaston et al., 1994). NO is involved in several types of acute and chronic inflammation (Ialenti et al., 1992). Overproduction of NO by type II NOS or iNOS is associated with the development of airway inflammation (Kharitonov et al., 1995). However, the basal level expression of iNOS was low in SAE and BTE cells and therefore was difficult to detect by immunocytochemistry using conventional fluorophores (Texas Red, fluorescein, etc.). To improve signal stability and quantitation, an optically stable, new class fluorophore for immunocytochemical detection was employed in this study. Detection of iNOS was based on fluorescence from streptavidin-linked inorganic semiconductor nanocrystals of cadmium selenide [(CdSe)ZnS]. As fluorescence of nanomaterial fluorophores was significantly brighter and more photostable than organic fluorophores such as Texas Red and fluorescein (Xiao and Barker, 2004; Xiao et al., 2005), we were able to detect iNOS in both unexposed and SM-exposed SAE and BTE cells.

The reduced overexpression of proinflammatory cytokines and iNOS by roxithromycin in SM-exposed SAE and BTE cells is in agreement with previous *in vivo* and *in vitro* studies (for a complete review see Tsai and Standiford, 2004) and further supports the contention that macrolides can inhibit the production of proinflammatory mediators and cytokines. This suppressive effect of roxithromycin may not be accounted for by its antimicrobial properties but rather by its anti-inflammatory actions, as evidenced by the fact that other antibiotics, such as amoxicillin, cefaclor, penicillin, and cephalosporin, had no such effects even at high concentration (data not shown). Thus the immunomodulatory effects of antibiotics appear to be specific to macrolides. Similar findings were made by Kohri et al. (2000).

The protective effect of roxithromycin on SM cytotoxicity could possibly be explained, at least in part, by its ability to inhibit the overexpression of pro-inflammatory cytokines and mediators. As mentioned previously, Qabar et al. (2005) reported that suppressed expression of the proinflammatory cytokines IL-8 and IL-6 in human epidermal keratinocytes led to increased viability of SM-treated cells. Also, 1- α , 25-dihydroxyvitamin D₃ enhanced cell proliferation in human skin cells stimulated with SM by suppressing expression of the inflammatory mediators IL-6 and IL-8 (Arroyo et al., 2003). On the other hand, Stone et al. (2003) reported that inflammatory cytokines, such as TNF- α and IL-1 β enhanced SM toxicity on murine macrophages.

The subcellular mechanism of the anti-inflammatory effect of macrolides remains unknown. However, it is well known that the expression of several genes involved

in the immune and inflammatory response (e.g., iNOS, TNF, IL-1, IL-6, IL-8) are regulated at the transcriptional level by nuclear factor- κ B (NF- κ B) (for a recent review, see Yang et al., 2005). Thus, it is conceivable that macrolide antibiotics may act as anti-inflammatory agents by preventing the activation of NF- κ B. Ichiyama et al. (2001) demonstrated that clarithromycin, another macrolide widely used clinically, inhibits NF- κ B-dependent reporter gene expression in transfected pulmonary epithelial cells, providing direct evidence in support of specific effects of macrolides on NF- κ B activation. However, it is now held that the molecular mechanism(s) by which macrolides inhibit pro-inflammatory cytokine responses in the respiratory epithelium varies depending upon the macrolide used, the activating stimulus, and the cell type examined (Tsai and Standiford, 2004). Thus, further studies are required to determine whether NF- κ B is the target molecule for roxithromycin in the signal transduction pathway in SM-exposed SAE and BTE cells.

CONCLUSIONS

In summary, our results show that roxithromycin has anti-cytotoxic and anti-inflammatory activities in human airway epithelial cells. These effects of roxithromycin depend on its ability to prevent the overproduction of proinflammatory cytokines and mediators. Thus, macrolide antibiotics can exert therapeutic effects independent of their antibacterial activity, suggesting that macrolide antibiotics may serve as potential vesicant respiratory therapeutics.

ACKNOWLEDGMENTS

Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the authors, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.

REFERENCES

- Amir, A., Chapman, S., Kadar, T., Gozes, Y., Sahar, R., and Allon, N., 2000: Sulfur mustard toxicity in macrophages: effect of dexamethasone. *J. Appl. Toxicol.*, **20**: S51-S58.
- Arroyo, C. M., Schafer, R. J., Kurt, E. M., Broomfield, C. A., and Carmichael, A. J., 1999: Response of normal human keratinocytes to sulfur mustard (HD): cytokine release using a non-enzymatic detachment procedure. *Hum. Exp. Toxicol.*, **18**, 1-11.

- Arroyo, C. M., Kan, R. K., Burman, D. L., Kahler, D. W., Nelson, M. R., Corun, C. M., Guzman, J. J., and Broomfield, C. A., 2003: Regulation of 1-alpha, 25-dihydroxyvitamin D3 on interleukin-6 and interleukin-8 induced by sulfur mustard (HD) on human skin cells. *Pharmacol Toxicol.*, **92**, 204-213.
- Bryskier, A., Neu, H. C., Butzler, J. P., and Tulkens, P. M., 1993: *Macrolides: chemistry, pharmacology and clinical uses*. Blackwell Publishers, 714 pp.
- Eisenmenger, W., Drasch, G., von Clarmann, M., Kretschmer, E., and Roider, G., 1991: Clinical and morphological findings on mustard gas [bis(2-chloroethyl)sulfide] poisoning. *J. Forensic Sci.*, **36**, 1688-1698.
- Emad, A., and Rezaian, G. R., 1997: The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure: analysis of 197 cases. *Chest*, **112**:734-738.
- Gaston, B., Drazen, J. M., Loscalzo, J., and Stamler, J. A., 1994: The biology of nitrogen oxides in the airways. *Am. J. Respir. Crit. Care Med.*, **149**, 538-551.
- Ialenti, A., Ianaro, A., Moncada, S., and Di Rosa, M., 1992: Modulation of acute inflammation by endogenous nitric oxide. *Eur. J. Pharmacol.*, **211**, 177-182.
- Ichiyama, T., Nishikawa, M., Yoshitomi, T., Hasegawa, S., Matsubara, T., Hayashi, T., and Furukawa, S., 2001: Clarithromycin inhibits NF-kappaB activation in human peripheral blood mononuclear cells and pulmonary epithelial cells. *Antimicrob. Agents Chemother.*, **45**, 44-47.
- Kharitonov, S. A., Wells, A. U., O'Connor, B. J., Cole, P. J., Hansell, D. M., Logan-Sinclair, R. B., and Barnes, P. J., 1995: Elevated levels of exhaled nitric oxide in bronchiectasis. *Am. J. Respir. Crit. Care Med.*, **151**, 1889-1893.
- Kohri, K., Tamaoki, J., Kondo, M., Aoshiba, K., Tagaya, E., and Nagai, A., 2000: Macrolide antibiotics inhibit nitric oxide generation by rat pulmonary alveolar macrophages. *Eur. Respir. J.*, **16**, 62-67.
- Konno, S., Asano, K., Kurokawa, M., Ikeda, K., Okamoto, K., and Adachi, M., 1994: Antiasthmatic activity of a macrolide antibiotic, roxithromycin: analysis of possible mechanisms in vitro and in vivo. *Int. Arch. Allergy Immunol.*, **105**, 308-316.
- Kooy, N. W., Royall, J. A., Ye, Y. Z., Kelly, D. R., and Beckman, J. S., 1995: Evidence for in vivo peroxynitrite production in human acute lung injury. *Am. J. Respir. Crit. Care Med.*, **151**, 1250-1254.
- Maziak, W., Loukides, S., Culpitt, S., Sullivan, P., Kharitonov, S. A., and Barnes, P. J., 1998: Exhaled nitric oxide in chronic obstructive pulmonary disease. *Am. J. Respir. Crit. Care Med.*, **157**, 998-1002.
- Morikawa, K., Oseko, F., and Morikawa, S., 1993: Immunomodulatory effect of fosfomycin on human B-lymphocyte function. *Antimicrob. Agents Chemother.*, **37**, 270-275.
- Nussler, A. K., and Billiar, T. R., 1993: Inflammation, immuno-regulation and inducible nitric oxide synthase. *J. Leukocyte Biol.*, **54**, 171-178.
- Papirmeister, B., Fiester, A. J., Robinson, S. I., and Ford, R. D., 1991: *Medical defense against mustard gas: toxic mechanisms and pharmacological implications*. CRC Press, 359 pp.
- Qabar, A., Nelson, M., Guzman, J., Corun, C., Hwang, B. J., and Steinberg, M., 2005: Modulation of sulfur mustard induced cell death in human epidermal keratinocytes using IL-10 and TNF-alpha. *J. Biochem. Mol. Toxicol.*, **19**, 213-225.
- Rubin, B. K., 2004: Immunomodulatory properties of macrolides: overview and historical perspective. *Am. J. Med.*, **117**, 2S-4S.
- Sabourin, C. L., Petrali, J. P., and Casillas, R. P., 2000: Alterations in inflammatory cytokine gene expression in sulfur mustard-exposed mouse skin. *J. Biochem. Mol. Toxicol.*, **14**, 291-302.
- Sase, K., and Michel, T., 1997: Expression and regulation of endothelial nitric oxide synthase. *Trends Cardiovasc. Med.*, **7**, 28-36.
- Smith, W. J., and Dunn, M. A., 1991: Medical defense against blistering chemical warfare agents. *Arch. Dermatol.*, **127**, 1207-1213.
- Stamler, J. S., Singel, D. J., and Loscalzo, J., 1992: Biochemistry of nitric oxide and its redox-activated forms. *Science*, **258**, 1898-1902.
- Stone, W. L., Qui, M., and Smith, M., 2003: Lipopolysaccharide enhances the cytotoxicity of 2-chloroethyl ethyl sulfide. *BMC Cell Biol.*, **4**, 1.
- Tilg, H., Trehu, E., Atkins, M. B., Dinarello, C. A., and Mier, J. W., 1994: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. *Blood*, **83**, 113-118.
- Tsai, W. C., and Standiford, T. J., 2004: Immunomodulatory effects of macrolides in the lung: lessons from in-vitro and in-vivo models. *Curr. Pharm. Des.*, **10**, 3081-3093.
- Xiao, Y., and Barker, P. E., 2004: Semiconductor nanocrystal probes for human metaphase chromosomes. *Nucleic Acids Res.*, **32**, e28.
- Xiao, Y., Telford, W. G., Ball, J. C., Locascio, L. E., and Barker, P. E., 2005: Semiconductor nanocrystal conjugates, FISH and pH. *Nat. Methods*, **2**, 723.
- Yang, C. M., Hsieh, H. L., and Lee, C. W., 2005: Intracellular signaling mechanisms underlying the expression of pro-inflammatory mediators in airway diseases. *Chang Gung Med. J.*, **28**, 813-823.
- Young, R. A., Gonzalez, J. P., and Sorkin, E. M., 1989: Roxithromycin: a review of its antibacterial activity, pharmacokinetic properties and clinical efficacy. *Drugs*, **37**, 8-41.

ANTI-CYTOTOXIC AND ANTI-INFLAMMATORY EFFECTS OF THE MACROLIDE ANTIBIOTIC ROXITHROMYCIN IN SULFUR MUSTARD-EXPOSED HUMAN AIRWAY EPITHELIAL CELLS


**Xiugong Gao^{1*}, Radharaman Ray², Yan Xiao³, Peter E. Barker³ and
Prabhati Ray¹**

¹Walter Reed Army Institute of Research
Silver Spring, MD 20910

²United States Army Medical Research Institute of Chemical Defense
Aberdeen Proving Ground, MD 21010

³National Institute of Standards and Technology
Gaithersburg, MD 20899

Sulfur Mustard Causes Airway Inflammation and Injury



2,2'-di(chloroethyl) sulfide, sulfur mustard (SM)


- ⚠ Potent alkylating compound.
- ⚠ Chemical warfare agent/Terrorism agent.
- ⚠ Low to moderate doses - upper respiratory tract; Higher doses - deep lung.
- ⚠ Airway inflammation, edema and pulmonary obstruction.
- ⚠ Massive release of destructive enzymes and mediators of inflammation.
- ⚠ There is no effective therapy for SM inhalation injury.



SM victim from WWI

Macrolides Have Anti-Inflammatory Activities

- Macrolides: broad spectrum antibiotics.
- Structure: a macrocyclic lactone ring with amino sugars attached.
- Roxithromycin: a representative macrolide approved by FDA.
- Effective in treating chronic airway inflammatory diseases.
- Independent of their bactericidal activity.
- Macrolides affect several pathways of the inflammatory process, including the production of proinflammatory cytokines/mediators.




Roxithromycin

Objectives

- ❁ Demonstrate the anti-cytotoxic and anti-inflammatory effects of roxithromycin in SM-exposed normal human small airway epithelial (SAE) cells and bronchial/tracheal epithelial (BTE) cells as *in vitro* models.
- ❁ Develop effective antidotes for SM inhalation injury.


Sulfur Mustard Caused Severe Cytotoxicity in SAE and BTE Cells



Cell viability measured by MTS assay, 24 hr after SM exposure

Roxithromycin Protected Against SM Toxicity

MTS Assay




Roxithromycin was added prior to SM (100 μM) exposure
Cell viability measured by MTS assay, 24 hr after SM exposure


Roxithromycin Protected Against SM Toxicity

Fluorescence Staining

SAE



BTE



Control

100 μ M RXM

100 μ M SM

100 μ M SM + 100 μ M RXM


Calcein AM/EthD-1 staining 24 hr after SM exposure

Live cells: green; Dead cells: red

How does roxithromycin protect ?


- Proinflammatory cytokines/mediators are involved in SM cytotoxicity and resultant cell death.
 - Suppression of proinflammatory cytokines protects against SM cytotoxicity.
 - Increased proinflammatory cytokine expression promotes SM-induced cell death.
- Study effects of roxithromycin on proinflammatory cytokines/mediators expression at protein and mRNA levels.

Roxithromycin Inhibited Proinflammatory Cytokine Release



Cytokine release from SAE cells measured by ELISA 24 hr after SM exposure

Roxithromycin Inhibited Proinflammatory Cytokine mRNA Expression



Cytokine mRNA from SAE cells measured by real-time RT-PCR
24 hr after SM exposure

Inducible Nitric Oxide Synthase (iNOS) is an Important Mediator of Inflammation

- ④ iNOS: inducible nitric oxide synthase, which catalyzes the synthesis of nitric oxide (NO).
- ④ NO is a pleiotropic mediator involved in cell-mediated immunity and inflammation.
- ④ Excessive production of NO contributes to the pathophysiology of inflammation and the resultant tissue damage.
- ④ The basal level expression of iNOS was low in SAE and BTE cells, and therefore difficult to detect by immunocytochemistry (ICC) using traditional fluorophores.
- ④ In this study, we developed a more sensitive ICC method, using quantum dots as fluorophores.


Quantum Dots Are a Novel Class of Fluorescent Biolabeling Reagent

What are quantum dots?

- Inorganic nanocrystals made from semiconductor material - cadmium selenide (CdSe).
- Absorb light and then re-emit the light in a different color, based on particle size

Advantages of quantum dots over organic dyes?


- Higher photostability.
- Higher intensity.
- Higher signal/noise ratio.



Schematic Diagram of Quantum Dot

Roxithromycin Inhibited iNOS Expression in SAE and BTE Cells

SAE



BTE


Control

100 μ M SM

100 μ M SM+100 μ M RXM

iNOS signals detected by the streptavidin-Qdot655 conjugates

Roxithromycin Inhibited iNOS Expression in SAE and BTE Cells



Conclusions

- ▶ Roxithromycin has anti-cytotoxic and anti-inflammatory activities in human airway epithelial cells, which likely depend on its ability to down-regulate the production of proinflammatory cytokines/mediators.
- ▶ Our results indicate that macrolide antibiotics may serve as potential vesicant respiratory therapeutics.
- ▶ Here, we have shown a potential therapeutic benefit of a FDA approved drug to treat sulfur mustard inhalation injury, for which there is no therapy available at present.

Acknowledgement

Hiroshi Ishida (WRAIR)


Michael Zidanic (WRAIR)

Betty Benton (USAMRICD)

Disclaimer



Material has been reviewed by the Walter Reed Army Institute of Research. There is no objection to its presentation and/or publication. The opinions or assertions contained herein are the private views of the author, and are not to be construed as official, or as reflecting true views of the Department of the Army or the Department of Defense.

Quantum Dot Conjugation




Multiple Colors of Quantum Dots

Quantum dots absorb light and then re-emit the light in a different color; the size of the quantum dots determines the color.




Single-Source Excitation for All Colors of Quantum Dots



MTS Assay for Cytotoxicity

- MTS: 3-(4,5)-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt.
- It is reduced by NADPH or NADH produced in metabolic active cells into a colored formazan product.
- The formazan product is soluble in tissue culture medium.
- The quantity of formazan product can be measured by absorbance at 490 nm.
- The absorbance is proportional to the number of living cells in culture.



CellTiter 96[®] AQueous One Solution Cell Proliferation Assay





Calcein AM/EthD-1 Assay for Cytotoxicity



Live cells are distinguished by the presence of ubiquitous intracellular esterase activity, which converts the virtually nonfluorescent cell-permeant calcein AM to the intensely fluorescent calcein, producing an intense uniform green fluorescence in live cells (ex/em ~495 nm/~515 nm).



Dead cells usually are characterized by damaged membranes. Ethidium homodimer-1 (EthD-1) enters dead cells and undergoes a 40-fold enhancement of fluorescence upon binding to nucleic acids, thereby producing a bright red fluorescence in dead cells (ex/em ~495 nm/~635 nm). EthD-1 is excluded by the intact plasma membrane of live cells.





LIVE/DEAD[®] Viability/Cytotoxicity Kit



ELISA for Cytokine Release Analysis

Enzyme-linked immunosorbent assay (ELISA) kit specific for human proinflammatory cytokines (IL-1, IL-6, IL-8 and TNF- α) was used to analyze cytokine release.



BD OptEIA™ ELISA Kits



Real Time RT-PCR for mRNA Quantification

Real time RT-PCR is the method of choice for quantification of cytokine profiles as it is very accurate and sensitive, allows a high throughput, and can be performed on very small samples.

- Total RNA was extracted from cells using RNAqueous®-4PCR Kit (Ambion).
- Reverse transcription was carried out using High-Capacity cDNA Archive Kit (Applied Biosystems).
- Real time RT-PCR was performed on ABI 7500 Fast Real-Time PCR System.
- Tagman Gene Expression Assays primer/probe sets were used.
- mRNA expression was evaluated using the relative quantification method.
- The “housekeeping” gene β -actin was used for normalization.

